Capricor Therapeutics (CAPR) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' Income from Continuing Operations fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 10498.83%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
- As of Q3 2025, Capricor Therapeutics' Income from Continuing Operations stood at -$24.6 million, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
- Capricor Therapeutics' 5-year Income from Continuing Operations high stood at -$829093.0 for Q4 2023, and its period low was -$25.9 million during Q2 2025.
- For the 5-year period, Capricor Therapeutics' Income from Continuing Operations averaged around -$9.3 million, with its median value being -$7.2 million (2023).
- In the last 5 years, Capricor Therapeutics' Income from Continuing Operations soared by 8921.39% in 2023 and then tumbled by 74565.53% in 2024.
- Over the past 5 years, Capricor Therapeutics' Income from Continuing Operations (Quarter) stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
- Its last three reported values are -$24.6 million in Q3 2025, -$25.9 million for Q2 2025, and -$7.0 million during Q4 2024.